TD Securities analyst Tim James downgrades Mullen Group (TSX:MTL) from Buy to Hold.
OKYO Pharma Plans Q4 2022 IND Filing Of OK-101 To Treat Dry Eye Disease With Subsequent Phase 2 Initiation
OK-101 to treat ocular diseases, including Dry Eye Disease (DED), uveitis, allergic conjunctivitis, and ocular pain.
Successful pre-IND meeting with FDA in Q1 2022 and novel speed to market potential.
IND